Tetanus toxoid adsorbed
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Tetanus toxoid adsorbed
- tetanus toxoid adsorbed
- Tetanus toxoid adsorbed
- ATC classification codes
- J07AM01
Sources for recorded values
- ChEMBL ID
- CHEMBL2108876
- RxNorm IDs (RxCUI)
- 798306
- First in class
- No
- Orphan designation
- No
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Brain Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0001657
- Subject identifier
- D001932
Open Targets indications
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
Reported adverse events
- Event
- drug hypersensitivity
- Reports
- 13
- Reporting signal score
- 45.4305
- NCT02193347
- NCT03927222
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (53)
- A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
- A Randomized, Open-Label, Parallel-Design Pharmacokinetic and Pharmacodynamic Interaction Study of TNM002 and Adsorbed Tetanus Vaccine
- A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
- A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate
- A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
- ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
- Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas
- Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
- An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
- Antibody Production in Immune Disorders
- Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)
- Characterisation of Human B Cell Maturation in Response to Vaccination
- Comparative Study of Two Tetanus Toxoid Vaccination Strategies: Cold Chain Versus Controlled Temperature Chain
- CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
- Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
- Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
- Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy
- Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
- Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
In development for (2)
- Brain cancer Phase 1
- Glioblastoma Phase 2